Neuropsychiatric Disease and Treatment (Jun 2022)
Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone – Clinical Cases
Abstract
Filipa Viegas, Tiago Ferreira, Cláudia Campos Mental Health Department Hospital Prof. Dr. Fernando Fonseca, Amadora, PortugalCorrespondence: Filipa Viegas, Mental Health Department Hospital Prof. Dr. Fernando Fonseca, IC-19, Amadora, 2720-276, Portugal, Tel +351 91 744 87 81, Email [email protected]: Cariprazine is a third-generation antipsychotic approved in Europe in 2017 for the treatment of schizophrenia. It presents distinct pharmacodynamic properties, such as D3/D2 partial agonism, preferential binding to D3 receptors, antagonism at the serotonin 5-HT2A and 5-HT2B receptors, partial agonism at 5-HT1A receptors, and low affinity to other receptors (including noradrenergic, histaminergic, and cholinergic). It has demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia with a safe side effect and metabolic profile.Methods: Here, we describe one clinical case of a patient that benefited from an add-on of cariprazine to a regimen of clozapine; and two clinical cases of patients that benefited from the switch from clozapine and paliperidone long-acting injectable to cariprazine.Results and Discussion: Those cases illustrate how cariprazine can be used in patients with schizophrenia in the treatment of both positive and negative symptoms, and when aiming to ameliorate the metabolic burden associated with other treatments. However, further studies are needed to consubstantiate those findings.Keywords: cariprazine, clozapine, paliperidone, schizophrenia, negative symptoms
